



JC10 Rec'd PTO 23 MAR 2005

10/501962

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent Application of:

Applicant(s): Braun, et al

Application No.: 10/501,962

(National Stage Application of
International Application No.
PCT/DE03/00124)

Int'l Filing Date: 17 January 2003

Priority Date: 18 January 2002 (German Patent
Application No. 102 01 862.6)

Title: CONJUGATE FOR TREATING
PROKARYOTIC INFECTIONS

Docket No.: 4121-170

Examiner: Not Yet Assigned

Art Unit: Not Yet Assigned

Customer No.: 23448

23448

FIRST CLASS MAIL CERTIFICATE

I hereby certify that I am mailing the attached documents to the
Commissioner for Patents on the date specified, in an envelope addressed
to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-
1450, and First Class Mailed under the provisions of 37 CFR 1.8.

Candace White

March 21, 2005

Date of Mailing

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450


Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO/SB/08A. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Supplemental Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

- ☐ 2. This Supplemental Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Supplemental Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- ☐ c. Attached is our check no. _____ in the amount of \$_____ in payment of the fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. _____ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ 3. This Supplemental Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Supplemental Information Disclosure Statement be considered. Attached is our check no. _____ in the amount of \$180.00 in payment of the petition fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. _____ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ a. I hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Supplemental Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

Respectfully submitted,




Marianne Fuierer

Reg. No. 39,983

Attorney for Applicant

INTELLECTUAL PROPERTY/
TECHNOLOGY LAW
Telephone: (919) 419-9350
Fax: (919) 419-9354
Attorney Ref: 4121-170



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sheet 1 of 1

COMPLETE IF KNOWN

Application Number	10/501,962
Submission Date	July 19, 2004
First Named Inventor	Braun, et al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	4121-170

FOREIGN PATENT DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AR	Sambrook, et al., Molecular Cloning, A Laboratory Manual (Second Edition), Cold Spring Harbor Laboratory Press, Pages 7.84-7.87 (1989).	
	AS	Nielsen, et al., Sequence Seltive Recognition of DNA by Strand Displacement with a Thymine-Substiuted Polyamide, Science, Vol. 254, 1497-1500, (December 1991).	
	AT	R.B. Merrifield, Solid Phase Peptide Synthesis I. The Synthesis of a Tetrapeptide, Volume 85, 2148-2151 (1963).	
Examiner signature		Date Considered	

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

¹ All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. § 1.98(a)(3)(i), according to MPEP 609 III A(3).

² Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. § 1.98(a)(3)(i), according to MPEP 609 III A(3).